HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Antiplatelet therapy in patients with diabetes mellitus.

Abstract
Platelets are key players in arterial thrombosis, and oral antiplatelet therapy is a cornerstone in the treatment and prevention of cardiovascular events. However, although currently approved antiplatelet drugs have proved successful in reducing cardiovascular events, platelet-dependent thrombosis remains an important cause of morbidity and mortality in patients with coronary artery disease. It is well-known that patients with diabetes mellitus (DM) have an increased risk of cardiovascular events and, therefore, understanding the mechanism of action and safety profile of antiplatelet drugs in this high-risk population is of particular interest. There is considerable inter-individual variation in the efficacy of established antiplatelet drugs, and high on-treatment platelet reactivity is associated with an increased risk of cardiovascular events, thus prompting the search for novel drugs against platelet-dependent thrombosis. New antiplatelet treatment strategies include drugs with more efficient and reversible platelet inhibition. This review discusses selective inhibitors of the platelet cyclooxygenase enzyme, thienopyridine and non-thienopyridine inhibitors of the platelet adenosine diphosphate receptor, phosphodiesterase inhibitors, and protease-activated receptor antagonists. An overview of currently available antiplatelet drugs is provided, focusing on benefits and limitations in patients with DM. Furthermore, the rationale for new oral antiplatelet drugs under development is discussed with particular focus on the potential role of these drugs to improve cardiovascular outcomes in patients with DM.
AuthorsErik L Grove, Soren Gregersen
JournalCurrent vascular pharmacology (Curr Vasc Pharmacol) Vol. 10 Issue 4 Pg. 494-505 (Jul 2012) ISSN: 1875-6212 [Electronic] United Arab Emirates
PMID22272895 (Publication Type: Journal Article, Review)
Chemical References
  • Phosphodiesterase Inhibitors
  • Platelet Aggregation Inhibitors
  • Purinergic P2Y Receptor Antagonists
  • Receptors, Thrombin
  • Receptors, Thromboxane
  • Aspirin
Topics
  • Animals
  • Aspirin (pharmacology, therapeutic use)
  • Blood Platelets (drug effects, metabolism)
  • Diabetes Mellitus, Type 1 (blood, complications, drug therapy, metabolism)
  • Diabetes Mellitus, Type 2 (blood, complications, drug therapy, metabolism)
  • Diabetic Angiopathies (prevention & control)
  • Drug Therapy, Combination
  • Humans
  • Phosphodiesterase Inhibitors (pharmacology, therapeutic use)
  • Platelet Aggregation Inhibitors (pharmacology, therapeutic use)
  • Purinergic P2Y Receptor Antagonists (pharmacology, therapeutic use)
  • Receptors, Thrombin (antagonists & inhibitors)
  • Receptors, Thromboxane (antagonists & inhibitors)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: